Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 10.41% | |
| Inside Day | Range Contraction | 10.41% | |
| Wide Bands | Range Expansion | 10.41% | |
| Gapped Down | Weakness | 10.41% | |
| Calm After Storm | Range Contraction | 6.43% | |
| Wide Bands | Range Expansion | 6.43% | |
| Calm After Storm | Range Contraction | 14.60% | |
| Wide Bands | Range Expansion | 14.60% | |
| Gapped Down | Weakness | 14.60% | |
| Gilligan's Island Sell Setup | Bearish Swing Setup | -3.72% |
Get a Trading Assistant
- Earnings date: Unknown
CERo Therapeutics Holdings, Inc. Description
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.
Classification
Sector: Other
Industry: Other
Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.8 |
| 52 Week Low | 0.0636 |
| Average Volume | 80,225,037 |
| 200-Day Moving Average | 1.78 |
| 50-Day Moving Average | 0.11 |
| 20-Day Moving Average | 0.14 |
| 10-Day Moving Average | 0.20 |
| Average True Range | 0.05 |
| RSI (14) | 64.66 |
| ADX | 44.77 |
| +DI | 53.59 |
| -DI | 13.25 |
| Chandelier Exit (Long, 3 ATRs) | 0.29 |
| Chandelier Exit (Short, 3 ATRs) | 0.22 |
| Upper Bollinger Bands | 0.30 |
| Lower Bollinger Band | -0.02 |
| Percent B (%b) | 0.83 |
| BandWidth | 229.32 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.03 |
| MACD Histogram | 0.0162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.32 | ||||
| Resistance 3 (R3) | 0.32 | 0.30 | 0.31 | ||
| Resistance 2 (R2) | 0.30 | 0.28 | 0.30 | 0.30 | |
| Resistance 1 (R1) | 0.27 | 0.27 | 0.29 | 0.27 | 0.30 |
| Pivot Point | 0.25 | 0.25 | 0.26 | 0.25 | 0.25 |
| Support 1 (S1) | 0.23 | 0.23 | 0.24 | 0.23 | 0.20 |
| Support 2 (S2) | 0.21 | 0.22 | 0.20 | 0.20 | |
| Support 3 (S3) | 0.18 | 0.21 | 0.19 | ||
| Support 4 (S4) | 0.18 |
